| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1769ddf69f6123787eb9b6f32070d077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e5fbdb2b31c9d7af515b9aa72d68221 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-35 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y502-01008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2020-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca869684a2acf8c21bb3172d3dbbf97e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7932d3648587e73ccba850882f30cb0f |
| publicationDate |
2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021009299-A1 |
| titleOfInvention |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process |
| abstract |
The molecular damages leading to the deterioration of cellular and tissue functions occur at different rate in different people. Thus methods for screening anti-aging agents are highly desirable. The present fulfils this need by providing fusions proteins wherein the Bcl-xL protein is fused to a stability-affecting protein. By inducing the degradation of the fusion protein and then restoring said expression is thus possible to rejuvenate a marker of cell aging. The apparition of the mono-deamidated form will indeed correlate with the aging progression of the cells and thus will offer a reliable system of identifying agents that are capable of slowing down the aging process. The preferred fusion protein is a fusion of Bcl-XL with the mutant L106P of FKBP12. |
| priorityDate |
2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |